Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research

Mon, 13 Jul 2026 07:30:00 -0400

DUBLIN, July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. Sponsored by Keenova, the retrospective, physician-reported, survey-based medical chart review study covered in the manuscript used real‑world clinical data to evaluate patient characteristics, treatment patterns, and physicians' assessments of outcomes among individuals with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM) who received Acthar Gel. The manuscript appears in the peer-reviewed Journal of Comparative Effectiveness Research and is available

Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research

Mon, 13 Jul 2026 07:30:00 -0400

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Wed, 08 Jul 2026 07:00:33 -0400

Keenova Therapeutics plc announced positive results from its Phase 3 clinical trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic condition that causes collagen nodules to form along the connective tissue supporting the arch of the foot.

The trial, designated EN3835-309, enrolled 436 participants and met its primary endpoint, showing a statistically significant improvement in pain versus placebo as measured by the Average Daily Pain Intensity on the Numeric Rating Scale. The study also met key ranked secondary endpoints related to difficulty and activity limitation as measured by the Foot Function Index scale.

Additional secondary measures, including

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Wed, 08 Jul 2026 07:00:33 -0400

Additional secondary measures, including

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Wed, 08 Jul 2026 07:00:33 -0400

Additional secondary measures, including

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Wed, 08 Jul 2026 07:00:00 -0400

DUBLIN, July 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX^® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic medical condition that causes nodules composed primarily of excess collagen to form in the connective tissue that supports the arch of the foot.

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Wed, 08 Jul 2026 07:00:00 -0400

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Wed, 08 Jul 2026 07:00:00 -0400

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Wed, 08 Jul 2026 07:00:00 -0400

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Wed, 08 Jul 2026 07:00:00 -0400

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Wed, 08 Jul 2026 07:00:00 -0400

Keenova Champions Men's Health Month with Education and Outreach

Mon, 01 Jun 2026 16:15:00 -0400

Reddit AMA and New Sexual Health Screening Tool Headline the Awareness Month

DUBLIN, June 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today its Men's Health Month initiative, reaffirming its commitment to advancing men's health by hosting a Reddit "Ask Me Anything" (AMA) focused on Peyronie's disease and launching a new provider intake tool designed to support conversations about sensitive health conditions.

Keenova Champions Men's Health Month with Education and Outreach

Mon, 01 Jun 2026 16:15:00 -0400

Reddit AMA and New Sexual Health Screening Tool Headline the Awareness Month

Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting

Fri, 15 May 2026 07:36:00 -0400

DUBLIN, May 15, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that new and final updated data from its dedicated ventral curvature analysis of Peyronie's disease and XIAFLEX^® (collagenase clostridium histolyticum) will be shared at the American Urological Association (AUA) annual meeting, taking place May 15–18, 2026. The data to be presented will highlight that the clinical effectiveness and safety of XIAFLEX (collagenase clostridium histolyticum) in patients with ventral curvature are consistent with outcomes observed in patients with other clinical presentations of Peyronie's disease.

Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting

Fri, 15 May 2026 07:36:00 -0400

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

Keenova Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 06:30:00 -0400

Strong First-Quarter Performance Driven by Acthar^® Gel¹ and XIAFLEX^®²

Pipeline Development, Synergy Plan Remain on Track

Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million

Conference Call and Webcast Today at 8:00 a.m. ET

First Quarter 2026 Highlights³

Acthar Gel net sales of $170 million
XIAFLEX net sales of $134 million
Net sales from continuing operations of $468 million
Loss from continuing operations of $114 million
Adjusted EBITDA from continuing operations of $174 million

DUBLIN, May 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc ("Keenova" or the "Company") today

StreetInsider.com News Articles

Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research

Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis

Keenova Champions Men's Health Month with Education and Outreach

Keenova Champions Men's Health Month with Education and Outreach

Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting

Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results

Keenova Reports First Quarter 2026 Financial Results